Last week I took part in a debate at the Cambridge Union on the motion “This house needs new drugs.” The motion was proposed by the chief executive of AstraZeneca, a global pharmaceutical company that is moving its global headquarters to Cambridge and emphasising science over marketing. The Cambridge Union is designed in part to […]
Progress in child health depends on research—an important message to remember as we face the imminent departure of the UK from the EU […]
Richard Lehman reviews the latest research in the top medical journals […]
Last week I discussed meldonium, which was banned by the World Anti-Doping Agency (WADA) in January 2016 for use by sportsmen and women, because it supposedly increases blood flow and therefore exercise capacity. Meldonium is the International Nonproprietary Name (INN) of 3-(2,2,2-trimethyldiazaniumyl)propanoate, an analogue of the immediate precursor of carnitine, trimethylaminobutyrate (Figure 1). Meldonium is […]